Improving pneumococcal and herpes zoster vaccination uptake: expanding pharmacist privileges.
OBJECTIVE
To investigate how state-authorized pharmacist immunization privileges influence pharmacist intervention effectiveness in delivering pneumococcal and herpes zoster vaccinations and assess the implications these privileges have on vaccination rates.


METHODS
Cross-sectional study of Walgreens vaccination records from August 2011 to March 2012.


METHODS
A random sample of patients having a claim for influenza vaccination in the study period was selected. Vaccination uptake rates for pneumococcal disease and herpes zoster were calculated for previously unvaccinated patients at high risk for these conditions. Rates were examined by state-level pharmacist privileges.


RESULTS
For states authorizing immunization by protocol or prescriptive authority, the 1-year pneumococcal vaccination uptake rate for previously unvaccinated, high-risk persons was 6.6%, compared with 2.5% for states requiring a prescription (P <.0001), and 2.8% for states with no authorization (P <.0001). For herpes zoster, the 1-year vaccination uptake rate was 3.3% for states authorizing per protocol/prescriptive authority, compared with 2.8% (not significant, P <.05) for states authorizing by prescription, and 1.0% for states with no authorization (P <.0001). A 148% increase of pneumococcal vaccination and a 77% increase of herpes zoster vaccination would result if all states granted pharmacists full immunization privileges.


CONCLUSIONS
This analysis demonstrates that states that offer pharmacists full immunization privileges have higher vaccination uptake rates than states with restricted or no authorization. Considering the suboptimal vaccination rates of pneumonia and shingles and the public health goals of 2020, states with limited or no immunization authorization for pharmacists should consider expanding pharmacist privileges for these vaccinations.
Michael S
MS
Taitel
Leonard E
LE
Fensterheim
Adam E
AE
Cannon
Edward S
ES
Cohen
D003157:Community Pharmacy Services; D003430:Cross-Sectional Studies; D005260:Female; D053061:Herpes Zoster Vaccine / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010595:Pharmacists / Q000331:legislation & jurisprudence; D022242:Pneumococcal Vaccines / Q000008:administration & dosage*; D024382:Professional Role; D013219:State Government; D014481:United States; D014611:Vaccination / Q000706:statistics & numerical data*
D053061:Herpes Zoster Vaccine; D022242:Pneumococcal Vaccines